| Literature DB >> 32131752 |
Yin-Yin Chen1,2,3, Ping-Feng Wu4,5, Chii-Shya Chen6, Ian-Horng Chen6, Wan-Tsuei Huang1,2, Fu-Der Wang7,8,9,10.
Abstract
BACKGROUND: Microbial infection is the main cause of increased morbidity and mortality in burn patients, especially infections caused by multiple drug-resistant organisms (MDRO). The purpose of this study was to explore major microbial trends in burn patients.Entities:
Keywords: Burn; Infection; Microbial
Mesh:
Substances:
Year: 2020 PMID: 32131752 PMCID: PMC7057658 DOI: 10.1186/s12879-020-4920-4
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Distribution of severity of burns and frequencies of surgery
| Variables | Number ( | Percentage (%) |
|---|---|---|
| Number of total body surface area (%) (mean ± SD; range) | 46.1 ± 29.1 | 5–92 |
| < 10 | 6 | 16.2 |
| 10–19 | 4 | 10.8 |
| 20–29 | 2 | 5.4 |
| 30–39 | 1 | 2.7 |
| 40–49 | 5 | 13.5 |
| 50–59 | 6 | 16.2 |
| 60–69 | 3 | 8.1 |
| 70–79 | 4 | 10.8 |
| 80–89 | 2 | 5.4 |
| > 90 | 4 | 10.8 |
| Number of third -degree burn severity (%) | ||
| < 10 | 3 | 8.1 |
| 10–19 | 1 | 2.7 |
| 20–29 | 3 | 8.1 |
| 30–39 | 1 | 2.7 |
| 40–49 | 3 | 8.1 |
| 50–59 | 4 | 10.8 |
| 60–69 | 4 | 10.8 |
| 70–79 | 3 | 8.1 |
| 80–89 | 1 | 2.7 |
| > 90 | 4 | 10.8 |
| Main site of the third -degree burn | ||
| 30–50% burn of upper limb, except wrist and hand | 18 | 48.6 |
| 30–50% burn of lower limbs | 18 | 48.6 |
| 30–50% burn of trunk | 15 | 40.5 |
| 30–50% burn of face, head, and neck | 10 | 27.0 |
| 20–50% burn of wrists and hands | 4 | 10.8 |
| 30–50% burn of multiple specified sites | 4 | 10.8 |
| Unspecified degree | 10 | 27.0 |
| Number of surgeries | ||
| 0 | 5 | 13.5 |
| 1 | 7 | 18.9 |
| 2 | 5 | 13.5 |
| 3 | 7 | 18.9 |
| 4 | 4 | 10.8 |
| 5 | 3 | 8.1 |
| 6 | 1 | 2.7 |
| Number of various surgical procedures | ||
| 1 | 4 | 10.8 |
| 2 | 1 | 2.7 |
| 4 | 2 | 5.4 |
| 5 | 2 | 5.4 |
| 6 | 3 | 8.1 |
| 7 | 4 | 10.8 |
| 8 | 2 | 5.4 |
| 9 | 1 | 2.7 |
| > 10 | 8 | 21.6 |
| Main types of surgery ( | ||
| Operations on skin and subcutaneous tissue | 94 | 66.2 |
| Operations on muscle, tendon, and fascia of hand | 18 | 12.7 |
| Other operations on vessels | 11 | 7.7 |
| Time spent of first surgery (mean ± SD; range) (minutes) | 58.5 ± 40.7 | 5–215 |
| Time spent of surgery during the 7 days before healthcare-associated infection (mean ± SD; range) (minutes) | 76.3 ± 57.3 | 8–269 |
Demographic and clinical characteristics of burn cases
| Variables | Number ( | Percentage (%) |
|---|---|---|
| Intensive care units | 24 | 64.9 |
| Gender | ||
| Male | 22 | 59.5 |
| Female | 15 | 40.5 |
| Inhalation injury | 32 | 86.5 |
| White blood cell (≥10,500 mm3) | 27 | 73.0 |
| Hematocrit < 35% | 8 | 21.6 |
| Serum sodium (≥146 mmol/L) | 6 | 16.2 |
| Serum potassium (≥5.5 mmol/L) | 4 | 10.8 |
| Serum creatinine (≥1.5 mg/dL) | 4 | 10.8 |
| Serum albumin (≤2.49 g/dL) | 0 | 0.0 |
| Endotracheal tube | 23 | 62.2 |
| Mechanical ventilator > 96 h | 16 | 43.2 |
| Central line catheter | 18 | 48.6 |
| Foley catheter | 13 | 35.1 |
| Hemodialysis | 2 | 5.4 |
| Extracorporeal membrane oxygenation | 1 | 2.7 |
| Bloodstream infection | 28 | 70.0 |
| Symptomatic urinary tract infection | 9 | 22.5 |
| Asymptomatic bacteriuria | 2 | 5.0 |
| Central nervous system infection | 1 | 2.5 |
| Mortality | 1 | 2.7 |
| mean ± SD | min-max | |
| Age (years) | 22 ± 6.2 | 13–38 |
| APACHE II scores | 14.3 ± 8.0 | 2–32 |
| LOS before the first isolated MDR ( | 17.7 ± 16.0 | 2–55a |
| Total LOS in hospital stay# | 85.4 ± 70.4 | 9–276a |
| Baux score | 24.5 ± 8.7 | 6–46 |
SD standard deviation, APACHE acute physiology and chronic health evaluation, LOS length of stay, MDR multi-drug resistant microbes
aThe highly abnormal values during the hospital stay were selected for the analysis
#The LOS is calculated throughout the hospital stay, and other data are within 3 months of hospitalization (from June 27 to October 31)
Distribution of microbial isolates by total body surface area and by days after admission
| Isolated pathogens | Total | % | Total body surface area (%) | days after admission | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| < 39 | 40–49 | 50–59 | 60–69 | 70–79 | 80–89 | > 90 | 1–3 | 4–7 | 8–14 | 15–30 | > 31 | |||
| Rate of culture-positive (%) | 47.5 | 21.4 | 44.6 | 36.4 | 53.7 | 55.6 | 43.7 | 57.4 | 39.4 | 73.7 | 48.7 | 56.8 | 41.7 | |
| Rate of MDRO in total culture-positive (%) | 31.0 | 0.96 | 8.7 | 16.3 | 20.2 | 19.2 | 18.3 | 16.3 | 1.9 | 5.8 | 8.7 | 33.7 | 50.0 | |
| | 2 | 0.6 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| | 38 | 11.3 | 1 | 4 | 8 | 9 | 4 | 6 | 6 | 0 | 2 | 1 | 11 | 24 |
| | 21 | 6.3 | 1 | 2 | 3 | 4 | 6 | 1 | 4 | 2 | 1 | 7 | 6 | 5 |
| other | 14 | 4.2 | 0 | 3 | 1 | 2 | 3 | 1 | 4 | 0 | 0 | 2 | 6 | 6 |
| | 9 | 2.7 | 1 | 1 | 2 | 3 | 2 | 0 | 1 | 4 | 0 | 1 | 0 | 4 |
| | 7 | 2.1 | 0 | 0 | 1 | 0 | 4 | 2 | 0 | 1 | 0 | 0 | 2 | 4 |
| Others | 6 | 1.8 | 0 | 0 | 1 | 0 | 2 | 1 | 2 | 0 | 0 | 0 | 1 | 5 |
| | 9 | 2.7 | 0 | 0 | 3 | 2 | 1 | 2 | 1 | 0 | 1 | 1 | 3 | 4 |
| | 8 | 2.4 | 0 | 0 | 0 | 4 | 1 | 1 | 2 | 0 | 0 | 1 | 2 | 5 |
| | 5 | 1.5 | 0 | 1 | 0 | 0 | 1 | 1 | 2 | 0 | 0 | 0 | 3 | 2 |
| | 4 | 1.2 | 1 | 1 | 0 | 0 | 2 | 0 | 0 | 1 | 1 | 0 | 1 | 1 |
| | 1 | 0.3 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| | 4 | 1.2 | 0 | 0 | 1 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 2 | 2 |
| | 3 | 0.9 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 2 | 0 | 0 | 1 | 0 |
| | 2 | 0.6 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Others | 10 | 3.0 | 0 | 0 | 1 | 1 | 2 | 4 | 2 | 0 | 0 | 4 | 0 | 6 |
| | 1 | 0.3 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| | 36 | 10.7 | 0 | 5 | 5 | 8 | 6 | 6 | 6 | 0 | 3 | 7 | 18 | 8 |
| | 13 | 3.9 | 0 | 0 | 2 | 0 | 4 | 4 | 3 | 0 | 1 | 0 | 2 | 10 |
| | 13 | 3.9 | 0 | 3 | 2 | 3 | 3 | 2 | 0 | 3 | 1 | 2 | 6 | 1 |
| 33 | 9.9 | 0 | 0 | 3 | 5 | 10 | 6 | 9 | 2 | 3 | 0 | 10 | 18 | |
| | 1 | 0.3 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| 13 | 3.9 | 0 | 1 | 2 | 1 | 3 | 3 | 3 | 2 | 2 | 1 | 4 | 4 | |
| 7 | 2.1 | 0 | 1 | 0 | 1 | 2 | 2 | 1 | 2 | 0 | 1 | 0 | 4 | |
| 5 | 1.5 | 0 | 0 | 0 | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 0 | |
| 4 | 1.2 | 0 | 0 | 0 | 1 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 4 | |
| 3 | 0.9 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | |
| 1 | 0.3 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | |
| 1 | 0.3 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | |
| 1 | 0.3 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | |
| Yeast | 25 | 7.5 | 1 | 0 | 8 | 7 | 9 | 0 | 0 | 2 | 2 | 4 | 17 | |
| | 14 | 4.2 | 2 | 0 | 2 | 5 | 2 | 3 | 1 | 3 | 2 | 4 | 4 | |
| Others | 6 | 1.8 | 0 | 0 | 0 | 0 | 3 | 2 | 1 | 0 | 1 | 0 | 0 | 5 |
| 0 | ||||||||||||||
MDRO multiple drug-resistant organisms, MRSA methicillin-resistant S. aureus, VRE vancomycin-resistant Enterococcus, CRKP carbapenem–resistant K. pneumonia, CRE, carbapenem-resistant Enterobacteriaceae, IRAB imipenem-resistant A. baumannii, PDRAB pandrug-resistant A. baumannii, PDR-PA pandrug-resistant P. aeruginosa
*PDRAB was defined as being resistant to aminoglycosides, antipseudomonal carbapenems, antipseudomonal fluoroquinolones, antipseudomonal penicillins+β-lactamase inhibitors, extended-spectrum cephalosporins, folate pathway inhibitors, penicillins+β-lactamase inhibitors, polymyxins, tetracycline
*PDRPA was defined as being resistant to aminoglycosides, antipseudomonal carbapenems, antipseudomonal cephalosporins, antipseudomonal fluoroquinolones, antipseudomonal penicillins+β-lactamase inhibitors, monobactams, phosphonic acids, polymyxins
Fig. 1Trends in distribution of microbial isolates by total body surface area in the culture-positive specimens
Fig. 2Trends in the main microbial isolates by days after admission in the hospital (Culture positive specimens)
Regression models of risk factors for multi-drug resistant microbes
| Variables | Logistic regression model | Cox regression model | ||||||
|---|---|---|---|---|---|---|---|---|
| Unadjust | Adjust | Unadjust | Adjust | |||||
| OR | OR | HR | HR | |||||
| Total body surface area (every 10%) | 3.6 (1.6–8.2) | .003 | 17.57 (1.47–21.0) | .024 | 1.31 (1.01–1.56) | .003 | 2.58 (1.71–3.88) | < .001 |
| Third burn-degree severity (every 10%) | 1.79 (1.2–2.6) | .002 | 0.26 (0.05–1.41) | .118 | 1.14 (0.99–1.32) | .076 | 0.53 (0.38–0.73) | < .001 |
OR odds ratio, CI confidence interval, HR hazards ratio